ライフサイエンスコーパス: adjuvant therapy

1 status, PR status, and HER2 status, and (neo)adjuvant therapy.

2 A total of 438 (85.9%) received adjuvant therapy.

3 rgery or on pathology; 31.8% (2168) received adjuvant therapy.

4 ts who would receive additional benefit from adjuvant therapy.

5 vascular disease, histological diagnosis and adjuvant therapy.

6 vant chemoradiation, surgical resection, and adjuvant therapy.

7 ct to studies and protocols on patients with adjuvant therapy.

8 with improved survival when compared with no adjuvant therapy.

9 drug is approved as either a monotherapy or adjuvant therapy.

10 colon cancer during the first 3 years after adjuvant therapy.

11 potential use of combination biomarkers for adjuvant therapy.

12 ial enrollment, metastatic surveillance, and adjuvant therapy.

13 an increased risk of metastasis and may need adjuvant therapy.

14 nagement of the primary and neck tumors, and adjuvant therapy.

15 apy/CCRT PET/CT scan within 1 wk of starting adjuvant therapy.

16 significant survival benefit compared to no adjuvant therapy.

17 ereas those with high GC scores benefit from adjuvant therapy.

18 ns, HBOT may be considered as an alternative adjuvant therapy.

19 se stage II patients who better benefit from adjuvant therapy.

20 dures, appropriate pathology techniques, and adjuvant therapy.

21 sis of breast cancer was referred to discuss adjuvant therapy.

22 djusting for age, stage of disease, and (neo)adjuvant therapy.

23 es, suggesting a role for cancer vaccines as adjuvant therapy.

24 r no optic nerve involvement and received no adjuvant therapy.

25 may prove beneficial in staging and guiding adjuvant therapy.

26 age colorectal cancer to refine selection of adjuvant therapy.

27 NM may help to better define the duration of adjuvant therapy.

28 creatic cancer support upfront resection and adjuvant therapy.

29 apy may offer benefit over surgery-first and adjuvant therapy.

30 edge, no studies have described a benefit of adjuvant therapy.

31 make more informed treatment decisions about adjuvant therapy.

32 Initial therapy includes surgery and adjuvant therapy.

33 ical status, tumor stage, and neoadjuvant or adjuvant therapy.

34 t extends survival much longer than standard adjuvant therapy.

35 cebo (1:1:1) for the duration of trastuzumab adjuvant therapy.

36 as definitive therapy or as a postoperative adjuvant therapy.

37 roved survival and a reduction in subsequent adjuvant therapies.

38 dentify patients who may benefit from future adjuvant therapies.

39 rgical extirpation and reliance on effective adjuvant therapies.

40 INK1 upregulation, and offers a strategy for adjuvant therapies.

41 criteria for randomized trials investigating adjuvant therapies.

42 these patients for the application of novel adjuvant therapies.

43 avenue of investigation for the delivery of adjuvant therapies.

44 nt selection is mandatory for neoadjuvant or adjuvant therapies.

45 ion are urgently needed to investigate novel adjuvant therapies.

46 nd can accelerate the evaluation of new (neo)adjuvant therapies.

47 could be initiated before administration of adjuvant therapies.

48 al (OS) could expedite the evaluation of new adjuvant therapies.

49 sk stratification, and select candidates for adjuvant therapies.

50 rapy (23.3 months) than cholecystectomy with adjuvant therapy (16.4 months), which was significantly

51 tly longer for extended cholecystectomy with adjuvant therapy (23.3 months) than cholecystectomy with

52 avien-Dindo complications, (2) initiation of adjuvant therapy, (3) completion of adjuvant therapy, an

53 mated groups had at least 3 years of planned adjuvant therapy (36.1% vs 65.9%; P < .001).

54 t routinely indicated; (3) consideration for adjuvant therapy; (4) further clinical trials; (5) multi

55 of postoperative complications on the use of adjuvant therapy after colectomy for cancer.

56 Data on optimal adjuvant therapy after complete resection of small-cell

57 cavity squamous cell carcinoma who received adjuvant therapy after radical surgery were included.

58 ients with BC with similar ER, nodal status, adjuvant therapy, age, and year of diagnosis.

59 itis are likely to be multidimensional, with adjuvant therapies aimed at modifying the immune respons

60 Adjuvant therapies aimed at reducing the immune response

61 ay readmission, 30-day mortality, and use of adjuvant therapies (all P > 0.05).

62 which was not seen in patients that received adjuvant therapy alone.

63 platin (mFOLFIRINOX) is the standard-of-care adjuvant therapy, although data from several randomized

64 There is no known effective adjuvant therapy, although various combinations have bee

65 With upfront resection and adjuvant therapy an actual overall 5YS rate of 18.8% can

66 investigated the relationship between these adjuvant therapies and subclinical cerebral small-vessel

67 als were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therap

68 tients met study criteria: 313 (78%) without adjuvant therapy and 90 who received adjuvant chemothera

69 patients and guide recommendations regarding adjuvant therapy and postoperative surveillance of patie

70 se patients may benefit from more aggressive adjuvant therapy and postoperative surveillance regimens

71 Patients were stratified by previous adjuvant therapy and randomly assigned (1:1) via a rando

72 n of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate

73 to select patients who may benefit from neo-adjuvant therapy and to avoid overtreatment in those pat

74 mortality, barotrauma, new use of hypoxemic adjuvant therapies, and ICU and hospital stay.

75 RINOX, (2) which patients might benefit from adjuvant therapy, and (3) survival differences between r

76 ation of adjuvant therapy, (3) completion of adjuvant therapy, and (4) overall survival RESULTS:: Pat

77 bjectives were tolerability, compliance with adjuvant therapy, and biomarker distribution.

78 ariable models that also included sex, prior adjuvant therapy, and BRAF mutational status.

79 d clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for

80 Perioperative morbidity, use of adjuvant therapy, and long-term survival were examined a

81 Imaging studies, surgical approach, adjuvant therapy, and pathology reports were reviewed.

82 Simple cholecystectomy with adjuvant therapy appears to be superior to extended rese

83 ssive screening or alternative approaches to adjuvant therapy are needed.

84 vantage compared with total laryngectomy and adjuvant therapy as indicated.

85 operation or an operation first followed by adjuvant therapy, as well as two separate prospective co

86 Patients received adjuvant therapy at physician's discretion.

87 MSI-H is not a predictive factor because the adjuvant therapy based on traditional cytotoxic agents d

88 without detriment to help select appropriate adjuvant therapy based on tumour Ki67.

89 nosis, it should be done after completion of adjuvant therapy (before 1 year).

90 radiotherapy is not clearly established, but adjuvant therapies can offer better outcomes in patients

91 Adjuvant therapy can be done to reduce the risk of recur

92 three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour

93 est that preventing or delaying relapse with adjuvant therapy could be beneficial in this setting.

94 To assess if simple cholecystectomy with adjuvant therapy could provide outcomes comparable to ex

95 radiotherapy, total mesorectal excision, and adjuvant therapy) currently applied to all patients with

96 lining influence of axillary nodal status on adjuvant therapy decision-making, ongoing clinical trial

97 into the clinical context may better inform adjuvant therapy decisions in stage III as well as stage

98 tumor biology are increasingly used to make adjuvant therapy decisions.

99 rectal cancer and may guide surveillance and adjuvant therapy decisions.

100 eated by primary enucleation with or without adjuvant therapy depending on histopathologic risk facto

101 opensity-score matching on lymph node ratio, adjuvant therapy, disease-free survival, and recurrence

102 ric location, which had an impact on planned adjuvant therapy duration.

103 ondrion-targeted ROS scavengers as potential adjuvant therapies during severe infections.

104 , multifunctional NMs synergize surgery with adjuvant therapy (e.g., chemotherapy, immunotherapy, pho

105 the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant i

106 Adjuvant therapy followed national standards.

107 ve neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly ex

108 cell lines may be useful for discovering new adjuvant therapies for aggressive thyroid cancers.

109 us therapeutics for deployment as primary or adjuvant therapies for epidermal disorders.

110 tant cancer prevention strategies as well as adjuvant therapies for improving outcomes.

111 ne key strategy for developing host-directed adjuvant therapies for tuberculosis (TB).

112 sectability rate 71%), of which 26 initiated adjuvant therapy for a total of 23 patients (60.5%) who

113 AC inhibitors might find therapeutic use as adjuvant therapy for advanced melanoma.

114 t study supports high-dose simvastatin as an adjuvant therapy for CAP + S in an older and milder dise

115 be warranted in the use of curcumin, even as adjuvant therapy for CNS lupus.

116 C and this approach might be promising as co-adjuvant therapy for cystic fibrosis.

117 chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer.

118 NT Aromatase inhibitors (AIs) are used as an adjuvant therapy for estrogen-receptor-positive breast c

119 As adjuvant therapy for high-risk stage III melanoma, ipili

120 Blood glucose control might be an adjuvant therapy for improving Guillain-Barre syndrome r

121 ials may be further explored as an effective adjuvant therapy for infected bone defects and/or osteom

122 ess of self- retained cryopreserved AM as an adjuvant therapy for infectious corneal ulcers.

123 Purpose Adjuvant therapy for intermediate-risk and high-risk loc

124 vaccines have had a record of failure as an adjuvant therapy for malignancies that are treated with

125 tus for survival outcome after resection and adjuvant therapy for pancreatic cancer.

126 sphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer.

127 We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected s

128 ubstantiate the NCCN guidelines recommending adjuvant therapy for patients with distal esophageal ade

129 There is no standard of care for adjuvant therapy for patients with hepatocellular carcin

130 the US Food and Drug Administration-approved adjuvant therapy for patients with high-risk melanoma.

131 s setting and should not be considered as an adjuvant therapy for patients with resected early-stage

132 of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two

133 uld be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-pos

134 dronate (1,600 mg/d orally) be considered as adjuvant therapy for postmenopausal patients with breast

135 at CMV-specific ACT can be safely used as an adjuvant therapy for primary GBM and, if offered before

136 Sorafenib should not be used as adjuvant therapy for RCC.

137 CXL used as adjuvant therapy for recalcitrant deep stromal fungal ke

138 e standard care with compression therapy and adjuvant therapy for refractory wounds, at present in cl

139 comparing neoadjuvant and surgery-first with adjuvant therapy for resectable pancreatic cancer.

140 uct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and p

141 Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal grow

142 hylactic cranial irradiation, relative to no adjuvant therapy for stage T1-2N0M0 SCLC.

143 verteporfin should be further explored as an adjuvant therapy for the treatment of glioblastoma.

144 of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cance

145 a subgroup of UR patients who also received adjuvant therapy-for early-stage resectable pancreatic a

146 Despite the development of adjuvant therapies, glioblastoma (GBM) patients remain i

147 American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell l

148 Adjuvant therapy had a tendency to correlate significant

149 y is the mainstay of treatment, but numerous adjuvant therapies have been applied to improve surgical

150 two additional trials of targeted agents as adjuvant therapies have not yet been published.

151 ight not receive the recommended duration of adjuvant therapy if their risk of recurrence is underest

152 Patients were excluded if 5-FU was used as adjuvant therapy, if they did not complete therapy, or i

153 In R1 patients adjuvant therapy improved survival and reduced distant r

154 Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients

155 present a valid strategy for neuroprotective adjuvant therapies in HAND.

156 Using adiponectin for adjuvant therapies in iron-overload cardiac dysfunction

157 whether such immunological markers may guide adjuvant therapies in stage III metastatic melanomas.

158 t in multidisciplinary decision-making about adjuvant therapies in this patient population.

159 ing the basis for an efficient combinatorial adjuvant therapy in clinical trials.

160 tial role for selenium supplementation as an adjuvant therapy in CML.

161 nstrate that CXCR7 is a potential target for adjuvant therapy in combination with androgen deprivatio

162 ble E2 delivery platform shows promise as an adjuvant therapy in craniofacial care of patients.

163 thereby highlighting its putative role as an adjuvant therapy in defined GBM patient populations.

164 hat glucagon antagonism could i) be a useful adjuvant therapy in diabetes only when residual insulin

165 -induced ALI in mice and may be useful as an adjuvant therapy in future pre-clinical studies.

166 point inhibitors are promising approaches to adjuvant therapy in kidney cancer, and a number of trial

167 rovide similar rates of remnant ablation and adjuvant therapy in low and intermediate risk patients w

168 s and Main Results: Four days of simvastatin adjuvant therapy in patients with CAP + S was associated

169 Tamoxifen is widely prescribed as adjuvant therapy in patients with early-stage breast can

170 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-posit

171 cy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcino

172 (HDI) has emerged as a potentially effective adjuvant therapy in patients with resected melanoma at h

173 Decisions regarding adjuvant therapy in patients with stage II colorectal ca

174 ion of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and

175 atic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers

176 indicating prednisolone may be an effective adjuvant therapy in some cases of DCK-negative AML.

177 ion may provide a more tailored approach for adjuvant therapy in stage II colon cancer.

178 ical data related to the benefit of FU-based adjuvant therapy in such patients.

179 tation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic

180 (TAI) was used as an effective postsurgical adjuvant therapy in the management of abdominal metastas

181 s highlight the potential of S. dentisani as adjuvant therapy in the management of periodontal diseas

182 s indicate that PACK-CXL may be an effective adjuvant therapy in the management of severe infectious

183 rioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficul

184 mphangiogenesis inhibitor, as a potential co-adjuvant therapy in the treatment of AML.

185 tus should help determine who should receive adjuvant therapy in this select subset of patients.

186 In-office sutureless AM may be an effective adjuvant therapy in treating sight-threatening infectiou

187 isease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast canc

188 Current carcinoma treatments include adjuvant therapy intended to kill the cryptic metastatic

189 ndent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal ar

190 Collectively, our findings suggest that adjuvant therapy is associated with improved EFS/OS in p

191 he utility of disease-staging modalities and adjuvant therapy is needed.

192 The delivery of postoperative adjuvant therapy is problematic in this disease because

193 Adjuvant therapy is recommended for high-risk patients w

194 referred choice or for high-risk cases where adjuvant therapy is recommended.

195 Oxaliplatin-based adjuvant therapy is the standard of care for stage III c

196 Adjuvant therapies may improve the outcome, but clinical

197 ermore, these studies suggest that effective adjuvant therapies may need to target the CSC population

198 ally identifying subgroups with the need for adjuvant therapy may be possible.

199 Strict criteria for adjuvant therapy may improve outcomes of children who un

200 If GTR is not achieved, adjuvant therapy might delay tumour progression or recur

201 d neoadjuvant therapy and surgery-first with adjuvant therapy (n = 22,285).

202 ed with a subset of UR patients who received adjuvant therapy, NAT patients had a better survival (ad

203 For making decisions regarding adjuvant therapy, nodal status, tumor size, estrogen rec

204 ation has a limited but relevant role in the adjuvant therapy of gastric cancer (GC) patients.

205 s and, hence, as a potential drug target for adjuvant therapy of solid tumors.

206 oxide by JP4-039 is a promising strategy for adjuvant therapy of these disorders.

207 ients using aromatase inhibitors (AIs) as an adjuvant therapy often report side effects, including ho

208 es and evaluating the impact of contemporary adjuvant therapies on the risk of CNS metastasis develop

209 ctions of the incremental effects of EOR and adjuvant therapy on survival.

210 tory approval for early clinical settings as adjuvant therapies or as first-line options for recurren

211 er risk of recurrence who would benefit from adjuvant therapies or more frequent surveillance, thereb

212 ery, postoperative complications, receipt of adjuvant therapy or overall survival.

213 alterations confer a favourable response to adjuvant therapy, or which signalling pathways might be

214 ns increased the likelihood of not receiving adjuvant therapy over twofold [odds ratio (OR) = 2.20, 9

215 gests that the beneficial effect of D-serine adjuvant therapy previously reported in PD patients may

216 Adjuvant therapy prolongs survival after resection of T2

217 high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically mea

218 ial surgical site infection did not decrease adjuvant therapy receipt but delayed the time to its use

219 t further consideration: tumor histology and adjuvant therapy recommendations, risk stratification to

220 s the primary consideration in breast cancer adjuvant therapy recommendations.

221 nts with residual tumour who did not receive adjuvant therapy, recurrence occurred early and Ki-67 LI

222 nefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age.

223 tial AC-T is likely to be the most effective adjuvant therapy regimen for early-stage breast cancer r

224 ork meta-analysis to test the most effective adjuvant therapy regimen in terms of overall survival (O

225 r Data Base from 2003 to 2011, stratified by adjuvant therapy regimen, was evaluated using Kaplan-Mei

226 tiple-relapse patients receiving LMP-CTLs as adjuvant therapy remained in remission at a median of 3.

227 Optimal duration of adjuvant therapy remains undefined.

228 dioactive iodine (RAI) is routinely used for adjuvant therapy, remnant ablation, and for the treatmen

229 ion regret, prognostication test result, and adjuvant therapy, respectively, while adjusting for age

230 dequacy of surgical staging should influence adjuvant therapy selection in the United States.

231 The risks and benefits of adjuvant therapy should be weighed before offering it to

232 5% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advant

233 alysis of interaction between MMR status and adjuvant therapy showed a trend toward improved progress

234 Adjuvant therapy significantly improved survival in pati

235 tion of patients insufficiently treated with adjuvant therapy so they can be offered secondary adjuva

236 tic tumors might be promising tools to study adjuvant therapy strategies for patients.

237 t, including 57% of patients who received no adjuvant therapy, suggesting that chemotherapy could be

238 Despite considerable research into adjuvant therapies targeting organ and tissue dysfunctio

239 Future studies may wish to focus on adjuvant therapies that augment IkappaKalpha/beta functi

240 ho lack HER2 amplification, may benefit from adjuvant therapy that targets HER2.

241 In the context of adjuvant therapy, the resection margin status remains an

242 Most low-risk patients can be cured without adjuvant therapy, thereby avoiding known long-term treat

243 prove the visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are

244 develop better-tolerated chemotherapies and adjuvant therapies to prevent anorexia and concurrent nu

245 reclinical evaluation of novel multimodal or adjuvant therapies to prevent recurrence and metastasis

246 Evidence for the use of various prophylactic adjuvant therapies to prevent vasospasm, including magne

247 e potential value of using antimiR-138 as an adjuvant therapy to alleviate this therapeutically intra

248 lts suggest that fidarestat could be used as adjuvant therapy to enhance DOX sensitivity of CRC cells

249 against CoV M(pro) through using zinc as an adjuvant therapy to enhance the efficacy of an irreversi

250 memory functions and FTY720 may be a useful adjuvant therapy to facilitate extinction of aversive me

251 tive cancer vaccines can offer a much needed adjuvant therapy to fill the treatment gap after liver r

252 ement definitive therapy with either neo- or adjuvant therapy to improve prognosis.

253 ents may require aggressive follow-up and/or adjuvant therapy to mitigate their poor outcomes.

254 CREB-Wnt signalling should be considered for adjuvant therapy to prevent breast cancer bone metastasi

255 client protein, SF3B2 may be developed as an adjuvant therapy to prevent neurotoxicity in cisplatin-b

256 as targeted therapeutic agents to be used in adjuvant therapy to promote resolution of inflammation a

257 erefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patien

258 e gut microbiota can potentially serve as an adjuvant therapy to retard development of cardiometaboli

259 ven after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast canc

260 rrently integrated into prognostic models or adjuvant therapy trials.

261 ent counseling and selection of patients for adjuvant therapy trials.

262 Despite recent improvement in adjuvant therapies, triple-negative, and ER(+) subtypes

263 ), or treatment factors (eg, neoadjuvant and adjuvant therapy use) differed between the groups.

264 es, craniotomy, corticosteroids as a main or adjuvant therapy, use of drains, irrigation of the hemat

265 Patients who received adjuvant therapy versus surgery alone were more likely t

266 ntrolled trials reporting on neoadjuvant and adjuvant therapies was conducted.

267 /4 complications was 14.2% and completion of adjuvant therapy was 65.6%.

268 Adjuvant therapy was administered to 59% of patients (n

269 Adjuvant therapy was defined as chemotherapy, with or wi

270 Adjuvant therapy was less frequently started in older pa

271 Management by excisional biopsy followed by adjuvant therapy was successful, and histopathology and

272 one propensity score matching for receipt of adjuvant therapy was used to account for potential selec

273 by recombinant human IFN-gamma (rhIFN-gamma) adjuvant therapy, we investigated macrophage functions f

274 Adjuvant therapies were given after primary tumor resect

275 5YS rates in patients with or without adjuvant therapy were 18.8% vs. 12.2%, respectively.

276 Incisional biopsy and excision without adjuvant therapy were associated with a poor outcome in

277 eatment or within 12 months of completion of adjuvant therapy-were randomly assigned (2:1) via a cent

278 am pathway, would provide a novel target for adjuvant therapy when treating pelvic cancers with radia

279 tients with PDR without HRC responded to the adjuvant therapy, whereas 75.0% of the eyes with PDR wit

280 ne metastases is not curative, therefore new adjuvant therapies which prevent the colonisation of dis

281 pecially poorly defined in terms of need for adjuvant therapies, which can be associated with both sh

282 Adjuvant therapy with an aromatase inhibitor improves ou

283 o are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxife

284 reast cancers can be successfully treated by adjuvant therapy with antiestrogens or aromatase inhibit

285 BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulte

286 sitive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anast

287 l, 353 patients with colon cancer undergoing adjuvant therapy with FOLFOX (fluorouracil, leucovorin,

288 Adjuvant therapy with imatinib benefits patients with a

289 This suggests that prefacing adjuvant therapy with integrin inhibitors is a viable cl

290 Adjuvant therapy with ipi3 benefits survival versus HDI;

291 At the 5-year follow-up, 1 year of extended adjuvant therapy with neratinib, administered after chem

292 Adjuvant therapy with nivolumab alone or in combination

293 es and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab in 35 patients with

294 to justify a clinical trial of breast cancer adjuvant therapy with statins and we advocate for such a

295 addition of ovarian suppression to standard adjuvant therapy with tamoxifen or with an aromatase inh

296 ended-duration anti-HER2 therapy, as well as adjuvant therapy with the anti-HER2 antibody-drug conjug

297 uscle invasive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy

298 colon cancer recurrence and mortality after adjuvant therapy with these newer options.

299 elated with poor long-term outcome following adjuvant therapy with trastuzumab.

300 174 postmenopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption